Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

(2016) Brenda J. Weigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group

(2016) Michael A. Arnold et al.   PEDIATRIC BLOOD & CANCER

Myogenin, AP2β, NOS-1, and HMGA2 Are Surrogate Markers of Fusion Status in Rhabdomyosarcoma

(2014) Erin R. Rudzinski et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Classification of Rhabdomyosarcoma and Its Molecular Basis

(2013) David M. Parham et al.   ADVANCES IN ANATOMIC PATHOLOGY

Dense Pattern of Embryonal Rhabdomyosarcoma, a Lesion Easily Confused With Alveolar Rhabdomyosarcoma

(2013) Erin R. Rudzinski et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

PAX-FOXO1fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

(2013) Stephen X. Skapek et al.   PEDIATRIC BLOOD & CANCER

The Inconvenience of Convenience Cohorts: Rhabdomyosarcoma and the PAX-FOXO1 Biomarker

(2012) A. R. Rosenberg et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Fusion Gene–Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma

(2010) Daniel Williamson et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Classification of Rhabdomyosarcoma—Genotypic and Phenotypic Determinants of Diagnosis

(2009) Elai Davicioni et al.   AMERICAN JOURNAL OF PATHOLOGY

Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups

(2008) Odile Oberlin et al.   JOURNAL OF CLINICAL ONCOLOGY